NOTE: KEI also submitted a 16-page in depth written submission to this investigation on March 20, 2023. The US International Trade Commission (ITC) will hold a hearing on March 29-30, 2023 on COVID–19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS… Continue Reading
On February 14, 2023, USDOJ filed a Statement of Interest of the United States, in the patent dispute between Arbutus Biopharma, Genevant Sciences, and Moderna. A copy of the filing is here: arbutus.moderna.USG.statementofinterest This is an important, and while not… Continue Reading
On Thursday, 7 July 2022, the 40th session of the Human Rights Council (HRC) adopted, by consensus, a resolution on Access to medicines, vaccines and other health products in the context of the right of everyone to the enjoyment of… Continue Reading
Updated Friday, 17 June 2022, 11:30 AM Geneva time. Early Friday morning, 17 June 2022, the WTO’s 12th Ministerial Conference (chaired by Timur Suleymenov, Kazakshstan), adopted a Ministerial Decision on the TRIPS Agreement (WT/MIN(22)/W/15/Rev.2). The text can be found here.… Continue Reading
The announcement was made by President Biden at the Global COVID-19 Pandemic Summit. KEI Statement on the NIH/C-TAP licenses Following an earlier promise from HHS Secretary Xavier Becerra, the NIH has entered into two licenses with the WHO COVID-19 Technology… Continue Reading
USTR-AmbTai-Bilateral-Plurilateal-agreements-3Dec2021 December 3, 2021 Ambassador Katherine Tai Office of the United States Trade Representative Washington, DC Dear Ambassador Tai, On November 18, 2021, Knowledge Ecology International (KEI) provided comments to USTR on three issues that were important for any WTO… Continue Reading
KEI sent this letter to USTR today regarding the TRIPS Waiver negotiations. Highlights what we think are the three most important issues. KEI-USTR-TRIPS-waiver-Priorities-18nov2021 November 18, 2021 Ambassador Katherine Tai Office of the United States Trade Representative Washington, DC Dear Ambassador… Continue Reading
On November 16, 2021, Pfizer and the Medicines Patent Pool (MPP) announced at voluntary license to patented inventions and know-how to manufacture a two drug combination to treat COVID-19. The MPP announcement is here and here. Additional comments on the… Continue Reading